Age: 58.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Myocardial infarction, SARS-CoV-2 test positive
Clinical narrative: got COVID; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (got COVID) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 005m21a, 012f21a, 007m20a and 039k20a) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: flu shot (after the heart attack) in December 2021. Past adverse reactions to the above products included No adverse event with flu shot. Concurrent medical conditions included Allergic reaction to antibiotics (doxycycline).   On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 21-Apr-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-Jun-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (got COVID). At the time of the report, COVID-19 (got COVID) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 18-Jun-2022, SARS-CoV-2 test: (Positive) Positive.         No concomitant medication was reported.  No treatment medication was reported. Company comment: This spontaneous case concerns a 58-year-old, female patient with no reported medical history, who experienced the unexpected, non-serious AESI of COVID-19. The event occurred 58 days after administration of fourth dose of mRNA-1273, the third dose was given 187 days prior, the initial two doses of mRNA-1273 were given approximately 8 months prior the third dose, the interval between the two doses is 28 days. On the day of onset of the event, SARS-CoV-2 test was done which revealed a positive result. It has been reported that the patient experienced an episode of heart attack 22 days after the administration of third dose of mRNA-1273. Details of concomitant medications, medical history, clinical course and treatment were not provided. The outcome of the event is unknown at the time of the report. The benefit-risk relationship of mRNA-1273 is not affected by this report.   This case was linked to MOD-2022-637942 (Patient Link).; Sender's Comments: This spontaneous case concerns a 58-year-old, female patient with no reported medical history, who experienced the unexpected, non-serious AESI of COVID-19. The event occurred 58 days after administration of fourth dose of mRNA-1273, the third dose was given 187 days prior, the initial two doses of mRNA-1273 were given approximately 8 months prior the third dose, the interval between the two doses is 28 days. On the day of onset of the event, SARS-CoV-2 test was done which revealed a positive result. It has been reported that the patient experienced an episode of heart attack 22 days after the administration of third dose of mRNA-1273. Details of concomitant medications, medical history, clinical course and treatment were not provided. The outcome of the event is unknown at the time of the report. The benefit-risk relationship of mRNA-1273 is not affected by this report.